Trial Profile
A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Familial Mediterranean fever
- Focus Therapeutic Use
- 18 Jun 2021 Results assessing real-life safety and efficacy of anakinra, published in the Rheumatology.
- 26 Nov 2016 New trial record
- 11 Nov 2016 Primary endpoint (Number of patients with less than a mean of one FMF attack per month) has been met according to the results published in the Arthritis and Rheumatology.